Combined targeting of STAT3 and STAT5: a novel approach to
overcome drug resistance in chronic myeloid leukemia

Karoline V. Gleixner, Mathias Schneeweiss, Gregor Eisenwort, Daniela
Berger, Harald Herrmann, Katharina Blatt, Georg Greiner, Konstantin
Byrgazov, Gregor Hoermann, Marina Konopleva, Islam Waliul, Abbarna
A. Cumaraswamy, Patrick T. Gunning, Hiroshi Maeda, Richard Moriggl,
Michael Deininger, Thomas Lion, Michael Andreeff, and Peter Valent

Contributions: Karoline V. Gleixner: Performed cell culture, Contributed primary samples,
Performed biologic assays, Plannned the study, Analyzed the data, Wrote the draft Mathias
Schneeweiss: Performed cell culture, Performed biologic assays, Performed flow cytometry
Harald Herrmann: Performed flow cytometry Katharina Blatt: Performed flow cytometry,
Performed biologic assays Daniela Berger: Conducted Western blot analysis Gregor
Eisenwort: Performed FACS sorting of transfected cells Georg Greiner: Performed
RNA-knock-down Konstantin Byrgazov: Generated and provided new cell lines Gregor
Hoermann: Performed RNA-knock-down Marina Konopleva: Contributed novel drugs
(CDDO-Me) Islam Waliul: Contributed novel drugs (SMA-ZnPP) Abbarna A.
Cumaraswamy: Contributed novel drugs (AC-3-019) Patrick T. Gunning: Contributed novel
drugs (AC-3-019) Hiroshi Maeda: Contributed novel drugs (SMA-ZnPP) Richard
Moriggl: Contributed novel drugs (AC-3-019) Michael Deininger: Generated and provided
new cell lines Thomas Lion: Generated and provided new cell lines Michael Andreeff:
Contributed novel drugs (CDDO-Me) Peter Valent: Provided logistic and budget support,
Approved the data and the final version of the manuscript

Disclosures: 1) This study was supported by Austrian Science Fund (FWF), grants
F4701-B20 F4704-B20 (to P.V.), F4705-B20 (to T.L.) and F4707-B20 (to R.M.) and by a
Grant-in-Aid from the Ministry of Welfare, Health and Labor of Japan, (201220042), and
A-STEP for cancer grant (AS242Z01542Q) from the Japan Science and Technology
Agency (to H.M.). 2) G.H.: Research Funding: Gilead; Honoraria: Novartis, Ariad, Amgen
M.K.: Equity Ownership: Reata Pharmaceuticals Consultancy and Research Funding:
Abbvie, GeneTech, Stemline; Research Funding: Eli Lilly, Cellectis, Calithera M.D.: 
Consultancy and Membership on an entity's Board of Directors or advisory committees: 
Ariad, Incyte; Consultancy and Research Funding: Bristol Myers Squibb; Membership on 
an entity's Board of Directors or advisory committees: CTI BioPharma Corp.; Research 
Funding: Gilead; Consultancy, Membership on an entity's Board of Directors or advisory 
committees and Research Funding: Novartis, Pfizer T.L.: Honoraria: Novartis, BMS, Pfizer, 
Ariad, Amgen; Research support: Novartis P.V.: Honoraria: Amgen Honoraria and 
Research Funding: Novartis, Celgene, Ariad; Pharmaceuticals Research; Funding: 
Deciphera All other authors have nothing to disclose. 3) There are no patents relevant to 
this work.